1029539-01-2

Basic information

• Product Name: Br^(1-)*C₁₄H₁₈ClN₄O⁽¹⁺⁾
• Synonyms: Br^(1-)*C₁₄H₁₈ClN₄O⁽¹⁺⁾
• CAS NO: 1029539-01-2
• Molecular Weight: 373.68
• Mol File: 1029539-01-2.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: Br^(1-)*C₁₄H₁₈ClN₄O⁽¹⁺⁾(CAS DataBase Reference)
• NIST Chemistry Reference: Br^(1-)*C₁₄H₁₈ClN₄O⁽¹⁺⁾(1029539-01-2)
• EPA Substance Registry System: Br^(1-)*C₁₄H₁₈ClN₄O⁽¹⁺⁾(1029539-01-2)

Safety Data

• Hazardous Substances Data: 1029539-01-2(Hazardous Substances Data)

Upstream product

• 100-97-0 hexamethylenetetramine 
• 41011-01-2 2-bromo-1-(3-chloro-phenyl)-ethanone 
• 99-02-5 3'-Chloroacetophenone 

Downstream Products

• 51084-83-4 2-amino-1-(3-chlorophenyl)ethanone hydrochloride 
• 1192424-45-5 C₁₉H₂₇ClN₂O₄S 
• 1192424-47-7 C₁₉H₂₆ClN₃O₂S 

Relevant articles and documents

BENZOPYRAZOLE COMPOUND USED AS RHO KINASE INHIBITOR

The invention relates to a benzopyrazole compound used as RHO kinase inhibitor, a pharmaceutical composition and uses thereof for preparing an RHO kinase inhibiting drug, and more specifically to said compound of formula (I-1), a pharmaceutically acceptable salt and isomer thereof.

COMPOUNDS HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY

This invention provides a compound of the formula (I): a pharmaceutically acceptable salt or solvate thereof, wherein R1 is substituted or unsubstituted alkyl or the like, R2 is hydrogen or substituted or unsubstituted alkyl, Ring A is monocyclic or bicyclic aromatic heterocycle, R3 is substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl or substituted or unsubstituted heterocycle, R4 is halogen, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl or the like, m is an integer between 0 and 2, n is an integer between 0 and 5, R is halogen, oxo, cyano, nitro, substituted or unsubstituted alkyl or the like, and p is an integer between 0 and 2 as novel compounds having NPY Y5 antagonistic activity.

COMPOUNDS WITH ACTIVITY AT RETINOIC ACID RECEPTORS

Disclosed herein is a compound of Formula (I) and pharmaceutical composition comprising the same. Also disclosed herein are methods of treating, or alleviating the symptoms of, a disease comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I). The disease may be selected from the group consisting of cancer, hyperproliferative disorder, inflammatory disorder, neurological disorder, neurodegenerative disorder, eye disorder, eye condition, depression, pulmonary disorders/conditions, dermatological disorders/conditions, and infertility.